Oct 20 (Reuters) – Natera Inc: * NATERA INC: SUCCESSFUL IMVIGOR011 TRIAL ACHIEVES 41% IMPROVEMENT IN OVERALL SURVIVAL FOR BLADDER CANCER PATIENTS Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post BRIEF-Natera Inc Says IMvigor011 Trial Achieves 41% Improvement In Overall Survival appeared first on The Sunday Guardian.

See Full Page